Clinical Trials Logo

Clinical Trial Summary

This proposal describes a single centre retrospective cross-sectional study which will address the need to further develop and test statistical risk prediction models for adverse maternal and neonatal outcomes in low-resource settings; this will be the first such research to be carried out in Zimbabwe.


Clinical Trial Description

Hypertensive disorders in pregnancy are a leading cause of maternal and perinatal morbidity and mortality, especially in low-resource settings. Identifying mothers and babies at greatest risk of complications would enable intervention to be targeted to those most likely to benefit from them. However, current risk prediction models have a wide range of sensitivity (42-81%) and specificity (87-92%) indicating that improvements are needed. Furthermore, no predictive models have been developed or evaluated in Zimbabwe. This proposal describes a single centre retrospective cross-sectional study which will address the need to further develop and test statistical risk prediction models for adverse maternal and neonatal outcomes in low-resource settings; this will be the first such research to be carried out in Zimbabwe. Data will be collected on maternal demographics characteristics, outcome of prior pregnancies, past medical history, symptoms and signs on admission, results of biochemical and haematological investigations. Adverse outcome will be defined as a composite of maternal morbidity and mortality and perinatal morbidity and mortality. Association between variables and outcomes will be explored using multivariable logistic regression. Critically, new risk prediction models introduced for our clinical setting may reduce avoidable maternal and neonatal morbidity and mortality at local, national, regional and international level. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04058405
Study type Observational
Source Mpilo Central Hospital
Contact
Status Completed
Phase
Start date November 12, 2018
Completion date August 31, 2021

See also
  Status Clinical Trial Phase
Terminated NCT04725812 - Complement Regulation to Undo Systemic Harm in Preeclampsia Phase 2
Active, not recruiting NCT03744988 - Serum Androgen Levels as a Marker for the Severity of Preeclampsia
Completed NCT02189148 - First-trimester Prediction of Preeclampsia
Completed NCT03164304 - Efficacy and Safety of 1 g Vs 2 g Per Hour Intravenous Maintenance Dose of MgSO4 in Women With Severe Pre-eclampsia Phase 4
Not yet recruiting NCT06265415 - Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine N/A
Completed NCT02379832 - Pre-Eclampsia And Growth Restriction: a Longitudinal Study
Not yet recruiting NCT01538121 - Antiphospholipid Antibodies and Early Severe Preeclampsia. N/A
Recruiting NCT01906567 - İs There a Relationship Between Severity of Preeclampsia and Maternal Heavy Metal Levels? N/A
Recruiting NCT01382732 - Carbetocin vs. Oxytocin for Prevention of Postpartum Bleeding in Patients With Severe Preeclampsia Phase 3
Completed NCT01408979 - Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia Phase 4
Completed NCT01538147 - Restless Leg Syndrome and Severe Preeclampsia N/A
Terminated NCT03008616 - Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclampsia Phase 2/Phase 3